New AI partnership to develop cardiovascular medication

British company Exscientia has been working with several pharmaceutical companies (including Sanofi, GlaxoSmithKline, and Roche), offering its artificial intelligence system to aid the drug discovery process. With the new announcement, Bayer are to back the project with €240 million ($266 million) over the course of three years. The focus of this digital transformation of the medication development process will be on the application of artificial intelligence to speed up the discovery of small molecule drug candidates. The drug candidates will have targets linked to oncology and cardiovascular disease. The deal between the two companies, as PharmaPorum reports, will see Bayer owning the rights to the compounds and Exscientia will receive royalties relating to future sales.